HSBC Holdings
KERX

HSBC Holdings’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

HSBC Holdings’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13,600
Closed -$80K – 2793
2016
Q4 		$80K Buy
+13,600
New +$74.3K ﹤0.01% 2640

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

HSBC Holdings's KERX Position: Q1 2017 in Review

HSBC Holdings sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2017, closing a stake of 13,600 shares — an estimated $80K sold.

HSBC Holdings first reported a position in KERX in Q4 2016 and held it in 1 quarter. The position peaked at $80K in Q4 2016. 119 funds tracked by Wall St. Rank hold KERX as of Q1 2017.

  • HSBC Holdings reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • HSBC Holdings sold 13,600 Keryx Biopharmaceuticals Inc shares in Q1 2017, an estimated $80K.
  • HSBC Holdings first reported a position in Keryx Biopharmaceuticals Inc in Q4 2016 and held it in 1 quarter.
  • HSBC Holdings's Keryx Biopharmaceuticals Inc position peaked at $80K in Q4 2016.
  • 119 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2017.

Based on HSBC Holdings's 13F filing for Q1 2017, filed 15 May 2017.